Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotigalimab + Nivolumab in Advanced NSCLC and Melanoma
NCT03123783Phase 2Completed
- Sponsor
- Apexigen, Inc.
- Start
- Jul 2017
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of sotigalimab in non-small cell lung cancer (NSCLC), melanoma, sponsored by Apexigen, Inc.. Started Jul 2017; status: completed.
02
Drugs
sotigalimab
03
Conditions
non-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT03123783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123783.